



# QUESTIONS TO ASK YOUR DOCTOR...


## ABOUT A TWO-DRUG REGIMEN

**The more you know about your treatment the better.**

A combination of active medicines is needed to treat HIV and achieve an undetectable HIV status in the body.<sup>1,2</sup> Some of these medicines may affect your day-to-day life and your body long-term. There are options, so why not ask if a 2-drug regimen might be a good choice for you?<sup>3</sup>

**THESE ARE A FEW QUESTIONS YOU CAN ASK AT YOUR NEXT VISIT TO HELP YOU AND YOUR DOCTOR MAKE THE BEST DECISION FOR YOU.**

**TICK OFF THE QUESTIONS THAT ARE IMPORTANT TO YOU**



**Add some questions of your own!**

- How many active ingredients are in my current regimen?
- Is changing medication an option for me?
- What are some other treatment options?
- Could they work for me?
- What short-term and long-term considerations should I have?
- Are there long-term effects of HIV treatment on my body?
- What would be the long-term benefit(s) of changing regimens?
- Are there different dosing options available?
- How are they different?
- What should I be thinking about when considering another medication?
- Will my viral load stay suppressed if I switch medications?
- Is it easy to go back on my previous medication(s) if I have to?

---


---

---

---


---

---



**FOR MORE INFORMATION ON 2-DRUG REGIMEN AND TIVICAY + LAMIVUDINE SCAN THE QR CODES**

**OR VISIT [WWW.2DR.CO.NZ](http://WWW.2DR.CO.NZ)**



**Abbreviation:** HIV, human immunodeficiency virus.

**References:** 1. FDA Approved HIV Medicines, Fact Sheet. HIV info NIH, 27 April 2022. Available at: <https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines> (accessed 08 March 2023). 2. NAM AIDS Map, Kasadha B. What does undetectable = untransmittable (U=U) mean? Updated April 2023. Available at: <https://www.aidsmap.com/about-hiv/faq/what-does-undetectable-untransmittable-uu-mean> (accessed 05 April 2023). 3. Chawla A, et al. *Infect Dis Ther* 2018 Jun;7(2):183-195.

**TIVICAY** (dolutegravir sodium), 50 mg film-coated tablets, is an integrase inhibitor, used for the treatment of Human Immunodeficiency Virus (HIV) infection in combination with other anti-HIV agents in adults and children over 12 years of age and weighing 40 kg or more. Tivicay is a funded medicine; Special Authority criteria apply. **DOVATO** (dolutegravir and lamivudine) is a film coated tablet containing 50 mg of dolutegravir (as dolutegravir sodium) and 300 mg of lamivudine, which is used for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component. Dolutegravir is an integrase inhibitor active against Human Immunodeficiency Virus (HIV). Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) and is a potent, selective inhibitor of HIV-1 and HIV-2. Dovato is not funded and is not supplied in New Zealand, this treatment option is available as separate medicines: Tivicay + Lamivudine. **TIVICAY and DOVATO are both prescription medicines. Tivicay and Dovato have risks and benefits and should only be prescribed by a doctor experienced in treating HIV. Ask your doctor if TIVICAY or DOVATO is right for you. Use strictly as directed.** If you have concerns, symptoms continue or if you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's consultation fees apply. You can view full Consumer Medicine Information at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Trademarks are owned by or licensed to the Viiv Healthcare group of companies. ©2023 Viiv Healthcare group of companies or its licensor. Marketed on behalf of Viiv Healthcare by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving Viiv Healthcare products should be reported to Viiv Healthcare Medical Information on 0800 808 500.** Date of Approval: **May 2023** and Date of Expiry: **May 2025**. TAPS-NP19318 PM-NZ-DLM-WCNT-230002.